- Home
- CWEN vs LGND Comparison
CWEN vs LGND Comparison
Compare CWEN & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CWEN
- LGND
- Stock Information
- Founded
- CWEN 2012
- LGND 1987
- Country
- CWEN United States
- LGND United States
- Employees
- CWEN N/A
- LGND 68
- Industry
- CWEN Electric Utilities: Central
- LGND Biotechnology: Pharmaceutical Preparations
- Sector
- CWEN Utilities
- LGND Health Care
- Exchange
- CWEN Nasdaq
- LGND Nasdaq
- Market Cap
- CWEN 3.7B
- LGND 3.2B
- IPO Year
- CWEN 2013
- LGND 1992
- Fundamental
- Price
- CWEN N/A
- LGND $184.49
- Analyst Decision
- CWEN Buy
- LGND Strong Buy
- Analyst Count
- CWEN 6
- LGND 8
- Target Price
- CWEN $36.00
- LGND $144.71
- AVG Volume (30 Days)
- CWEN 1.2M
- LGND 139.7K
- Earning Date
- CWEN 10-29-2025
- LGND 08-05-2025
- Dividend Yield
- CWEN 5.44%
- LGND N/A
- EPS Growth
- CWEN N/A
- LGND N/A
- EPS
- CWEN 0.64
- LGND N/A
- Revenue
- CWEN $1,432,000,000.00
- LGND $181,488,000.00
- Revenue This Year
- CWEN $6.56
- LGND $18.41
- Revenue Next Year
- CWEN $12.53
- LGND $18.87
- P/E Ratio
- CWEN $49.82
- LGND N/A
- Revenue Growth
- CWEN 14.65
- LGND 53.40
- 52 Week Low
- CWEN $24.40
- LGND $81.74
- 52 Week High
- CWEN $33.22
- LGND $129.90
- Technical
- Relative Strength Index (RSI)
- CWEN 62.39
- LGND 79.42
- Support Level
- CWEN $27.97
- LGND $179.40
- Resistance Level
- CWEN $32.48
- LGND $184.26
- Average True Range (ATR)
- CWEN 0.76
- LGND 4.60
- MACD
- CWEN 0.43
- LGND 0.44
- Stochastic Oscillator
- CWEN 74.02
- LGND 100.00
About CWEN Clearway Energy Inc. Class C
Clearway Energy Inc is a publicly-traded energy infrastructure investor with a focus on investments in clean energy and owner of modern, sustainable and long-term contracted assets across North America. The company segments its operations into Flexible Generation, renewables and Corporate divisions.
About LGND Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.